

Lenvatinib CLEAR

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS


Quality of life



Serious and disabling adverse effects



Other adjustments



Early stopping or crossover

Lenvatinib CLEAR

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers
Therapeutic Indication: Treatment of adults with advanced renal cell carcinoma in combination with pembrolizumab as first-line treatment
Experimental Arm: Lenvatinib + Pembrolizumab
Control Arm: Sunitinib

